Home >> Node

Dr. Jon H. Condra

Dr. Jon H. Condra

Selected Publications and Presentations:


1. Condra, J.H., W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K.E. Squires, P.J. Deutsch and E.A. Emini (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.

2. Condra, J.H., D.J. Holder, W.A. Schleif, O.M. Blahy, R.M. Danovich, L.J. Gabryelski, D.J. Graham, D. Laird, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J.A. Chodakewitz, P.J. Deutsch, R.Y Leavitt, F.E. Massari, J.W. Mellors, K.E. Squires, R.T. Steigbigel, H. Teppler and E.A. Emini (1996). Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology 70:8270-8276.

3. Condra, J.H. and E.A. Emini (1997). Preventing HIV-1 drug resistance. Science & Medicine 4(1):14-23.

4. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, D.D. Richman, F.T. Valentine, L. Jonas, A. Meibohm, E.A. Emini, P. Deutsch, D. Holder, W.A. Schleif, J.H. Condra and J.A. Chodakewitz (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337:734-739.

5. Condra, J.H. (1998). Resisting resistance: maximizing the durability of antiretroviral therapy. Annals of Internal Medicine 128:951-954.

6. Emini E.A. and J.H. Condra. Protease inhibitors. In: Merigan T.C., Bartlett J.G., Bolognesi D., ed. The Textbook of AIDS Medicine, Second ed. Baltimore, MD: Williams & Wilkins, 1998, pp. 848-859.

7. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, L. Jonas, A. Meibohm, D. Holder, W.A. Schleif, J.H. Condra, E.A. Emini, R. Isaacs, J.A. Chodakewitz and D.D. Richman (1998). Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100-week follow-up. Journal of the American Medical Association.280:35-41.

8. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, J.H. Condra, F.T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E.A. Emini, J.A. Chodakewitz, R. Isaacs and D.D. Richman (2000). 3-year suppression of HIV viremia with indinavir, zidovudine and lamivudine. Annals of Internal Medicine 133(1):35-39.

9. Para, M.F., D.V. Glidden, R.W. Coombs, A.C. Collier, J.H. Condra, C. Craig, R. Bassett, R. Leavitt, S. Snyder, V. McAuliffe and C. Boucher, for the AIDS Clinical Trials Group Protocol 333 Team (2000). Baseline human immunodeficiency virus type 1 phenotype, genotype and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. Journal of Infectious Diseases 182(3):733-743.

10. Condra, J.H., C.J. Petropoulos, R. Ziermann, W.A. Schleif, M. Shivaprakash and E.A. Emini (2000). Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. Journal of Infectious Diseases 182(3):758-765.

11. Condra, J.H. and J.P. Vacca (2002). HIV-1 protease inhibitors. In: Emini, E.A., ed. The Human Immunodeficiency Virus: Biology, Immunology and Therapy, Princeton, NJ: Princeton University Press: pp. 172-222.

12. Condra, J.H., M.D. Miller, D.J. Hazuda and E.A. Emini (2002). Potential new therapies for the treatment of HIV-1 infection. Annual Review of Medicine 53:541-555.

13. Saah, A.J., D.W. Haas, M.J. Nubile, J. Chen, D.J. Holder, R.R. Rhodes, M. Shivaprakash, K.K. Bakshi, R.M. Danovich, D.J. Graham and J.H. Condra (2003). Treatment with indinavir, efavirenz and adefovir after failure of nelfinavir therapy. Journal of Infectious Diseases 187 (1 April):1157-62.

14. Campo, R.E., J.N. Moreno, G. Suarez, N. Miller, M.A. Kolber, D.J. Holder, M. Shivaprakash, D.M. DeAngelis, J.L. Wright, W.A. Schleif, E.A. Emini and J.H. Condra (2003). Efficacy of indinavir/ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. AIDS 17:1933-1939.

15. Finnefrock, A.C., X. Liu, D.W. Opalka, J.W. Shiver, D.R. Casimiro and J.H. Condra (2007). HIV-1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses. AIDS Research and Human Retroviruses 23(10):1283-1292.

16. Montgomery, D.L., Y.-J. Wang, R. Hrin, M. Luftig, B. Su, M.D. Miller, F. Wang, P. Hatyko, L. Huang, S. Vitelli, J. Condra, X. Liu, R. Hampton, A. Carfi, A. Pessi, E. Bianchi, J. Joyce, C. Lloyd, R. Geleziunas, D. Bramhill, V.M. King, A. Finnefrock, W. Strohl and Z. An (2009). Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. mAbs 1(5): 1-12.

17. Ni, Y.G., J.H. Condra, L. Orsatti, X. Shen, S. DiMarco, S. Pandit, M.J. Bottomley, L. Ruggeri, R.T. Cummings, R.M. Cubbon, J.C. Santoro, A. Ehrhardt, D. Lewis, T.S. Fisher, S. Ha, L. Njimoluh, D.D. Wood, H.A. Hammond, D. Wisniewski, C. Volpari, A. Noto, P. Lo Surdo, B. Hubbard, A. Carfi and A. Sitlani (2010). A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen binding fragment inhibits PCSK9 internalization and restores LDL-uptake. Journal of Biological Chemistry 285:12882-12891.

18. Ni,Y.G., S. Di Marco, J.H. Condra, L.B. Peterson, W. Wang, F. Wang, S. Pandit, H.A. Hammond, R. Rosa, R.T. Cummings, D.D. Wood, X. Liu, M.J. Bottomley, X. Shen, R.M. Cubbon, S-P. Wang, D. Johns, C. Volpari, , L. Hamuro, J. Chin, L. Huang, J.Z. Zhao, S. Vitelli, P. Haytko, D. Wisniewski, L.J. Mitnaul, C.P. Sparrow, B. Hubbard, A. Carfí and A. Sitlani (2011). A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of Lipid Research 52(1):78-86.

19. Zhang, L., T. McCabe, J.H. Condra, Y.G. Ni, L.B. Peterson, W. Wang, A.M. Strack, F. Wang, S. Pandit, H. Hammond, D. Wood, D. Lewis, R. Rosa, V. Mendoza, A.M Cumiskey, D.G. Johns, B.C. Hansen, X. Shen, N. Geoghagen, K. Jensen, L. Zhu, K. Wietecha, D. Wisniewski, L. Huang, J.Z. Zhao, R. Ernst, R. Hampton, P. Haytko, F. Ansbro, S. Chilewski, J. Chin, L.J. Mitnaul, A. Pellacani, C.P. Sparrow, Z. An, W.R. Strohl, B. Hubbard, A.S. Plump, D. Blom, and A. Sitlani(2012). An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. International Journal of Biological Sciences 8(3): 310-327.

Temple University

Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140